Search Results
Apr 22, 2026, 09:30 ET Made Scientific and Regenicin Announce Manufacturing Relationship to Advance NovaDerm Toward FDA Product Approval
Investigational New Drug (IND) submission and upcoming clinical trial."We are proud to work with Regenicin to advance NovaDerm into the clinic," said Syed T. Husain, Chairman and CEO of Made Scientific. "This collaboration reflects the strength of our manufacturing platform and our ability to execute complex
More news about: Made Scientific, Inc.
Apr 22, 2026, 09:05 ET DR.G EXPANDS INTO THE U.S. WITH NEW INNOVATIVE SKINCARE LAUNCHES, BRINGING K-BEAUTY DERMATOLOGICAL EXPERTISE TO A GLOBAL STAGE
Mist Serum: A high-performance collagen mist that delivers deep hydration while improving elasticity and firmness. Powered by Black Snail extract and T3 Collagen, this ultra-fine mist absorbs quickly for a refreshed, dewy finish—without stickiness. Clinically proven to reduce the appearance of wrinkles
More news about: Dr.G
Apr 22, 2026, 09:00 ET Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients
CD28-mediated effector-T cell costimulation, without blocking CTLA-4, an important protein found on T cells that naturally helps keep the body's immune responses in check. Pegrizeprument is, therefore, expected to have a dual mechanism of action where in a direct manner, it blocks CD28-mediated T cell activation,
More news about: Veloxis Pharmaceuticals
Apr 22, 2026, 09:00 ET Reach Agency Expands Team by 25% to Accommodate Accelerated Agency Growth
Juice: Ma joins Reach from Open Influence, where she managed campaigns across a $5M+ portfolio. She's led initiatives across brands including AT&T, Constellation Brands Inc., FOX, Ariat and Bath and Body Works.
More news about: Reach Agency
Apr 22, 2026, 08:53 ET $500,000 Michael F. Price Memorial Grant from DeGregorio Family Foundation Awarded for Novel Gastroesophageal Cancer Therapy
often poor because of other cells in the vicinity of the tumor, such as immunosuppressive neutrophils (white blood cells) that inhibit the ability of T cells to kill the tumor. Furthermore, these neutrophils are abundant in advanced gastric cancers and are thought to indicate a bad prognosis. Dr
More news about: DeGregorio Family Foundation
Apr 22, 2026, 08:45 ET Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH,
More news about: Anixa Biosciences, Inc.
Apr 22, 2026, 08:36 ET Philadelphia Teen Sisters Earn Prestigious PRSA Silver Anvil Finalist While Expanding Charity to Help Shelter Animals
inspired by the sisters' own rescue dogs Toby and Bear, and their (non-rescue) hypoallergenic cats Turtle and Oreo.The charity is supported by AT&T, Drive David (David Auto), Veronica Beard, Kendra Scott, The Do Gooders Philadelphia, Karma For Cara, ILYAN jewelry, artist Jessie Tristan Read, and
More news about: Bored No More charity
Apr 22, 2026, 08:30 ET M&T Bank Corporation to Participate in the Barclays Americas Select Franchise Conference
April 22, 2026 /PRNewswire/ -- M&T Bank Corporation ("M&T") (NYSE: MTB) will participate in the Barclays Americas Select Franchise Conference being held in London. Representatives of M&T are scheduled to deliver a presentation to investors and analysts on
More news about: M&T Bank Corporation
Apr 22, 2026, 07:30 ET SIS Unveils Fixed-Price ERP Implementation Program for Mid-Sized Specialty Contractors
handling of equipment as rentals or owned; standard reports covering over/underbilling, AR aging, and margin/fade; invoicing options in AIA-style or T&M formats; and straight-line depreciation across 4–6 asset types.Supported by more than 25 years of construction ERP experience, SIS brings specialized
More news about: SIS, LLC
Apr 22, 2026, 07:30 ET TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.For more information, please visit
More news about: TuHURA Biosciences, Inc.
Apr 22, 2026, 07:01 ET DENARIUS METALS ANNOUNCES FIRST QUARTER 2026 PRODUCTION RESULTS FOR ITS ZANCUDO PROJECT IN COLOMBIA
and fourth quarters of 2025, respectively, to 2,337 tonnes in the first quarter of 2026. Head grades in the first quarter averaged 11.5 g/t for gold and 269.3 g/t for silver resulting in total revenue for the first quarter of 2026 of approximately US$3.5 million, up from US$1.7 million reported for our
More news about: Denarius Metals Corp.
Apr 22, 2026, 06:36 ET AT&T Reports Strong First-Quarter 2026 Financial Results
1Advanced home internet connections with AT&T wireless is defined as AT&T Fiber and AT&T Internet Air connections that are also primary wireless account holders that subscribe to consumer postpaid phone service. AT&T refers to these customers as converged customers. Convergence
More news about: AT&T
Apr 22, 2026, 02:46 ET NEW TELE-DENTISTRY PROGRAMME SUPPORTS EARLY INTERVENTION FOR CHILDREN AT RISK OF CARIES
[2] Chong SC, Aishworiya R, Seo WL, Chiong YK, Koh GC, Lin JB, Heng L, Habib Mohd T, Saw YE, Chan YH, Chua JS, Shorey S. Health practices, behaviours and quality of life of low-income preschoolers: A community-based cross-sectional comparison
More news about: National University Health System (NUHS)
Apr 22, 2026, 00:01 ET U.S. News Announces the 2026 Best Hybrid and Electric Cars
Rivian R1T for the first time. The
More news about: U.S. News & World Report, L.P.
Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
series is on track to deliver a late lead which meets the dose criteria for prophylaxis, i.e. a single dose <500mg for t>MIC for 7d (minimum) or a single dose <500mg for t>MIC for 28d (ideal). 3. Addressing the hERG inhibition
More news about: GHIT Fund
Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
series is on track to deliver a late lead which meets the dose criteria for prophylaxis, i.e. a single dose <500mg for t>MIC for 7d (minimum) or a single dose <500mg for t>MIC for 28d (ideal). 3. Addressing the hERG inhibition
More news about: GHIT Fund
Apr 21, 2026, 21:30 ET Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase
More news about: Nektar Therapeutics
Apr 21, 2026, 19:30 ET ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026
Mary's Hospital, who served as the principal investigator of the study.VT-EBV-N is an Epstein-Barr virus (EBV)-specific T cell therapy being developed for the treatment of NK/T-cell lymphoma, a rare and aggressive malignancy with a high risk of relapse.According to the company, the Phase 2 study
More news about: ViGenCell Inc.
Apr 21, 2026, 18:11 ET DRVN Investor Alert: Driven Brands Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action Alleging Pervasive Accounting Errors and Internal Control Failures - Hagens Berman
www.youtube.com/watch?v=EwsGKJAAbdM&t=2sIf you'd like more information and answers to additional frequently asked questions about the Driven case and the firm's
More news about: Hagens Berman Sobol Shapiro LLP